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Summary: Twenty-four-hour urine specimens from 21 juvenile insulin-dependent diabetics and 10 healthy controls
were compared with respect to biotinidase activity and alanine content. Urinary biotinidase activity was analysed
by a newly developed high-performance liquid chromatography (HPLC) method. It was found that the excretion of
biotinidase in urine was elevated in diabetics (7.02 mU/d; p < 0.005) as compared with controls (not detectable).
Alanine excretion was also found to increase (p < 0.01) in diabetics. Biotinidase excretion in diabetics was corre-
lated with alanine excretion (rS = 0.667; p < 0.01), but not with protein, albumin or N-acetyl- -glucosaminidase
excretion. The simultaneous elevation of urinary biotinidase and alanine excretion in juvenile diabetics suggests
that changes in kidney metabolism arise in the early stages of diabetes.
Introduction
Diabetic nephropathy develops particularly often among
patients with juvenile onset diabetes mellitus, in which
the cumulative risk of nephropathy is about 30—40%.
Morphological changes in the capillary basement mem-
brane and microalbuminuria are readily detectable in the
kidney of early diabetic nephropathy patients (1—3).
The current chemical standard for detecting nephropathy
is micro-albuminuria (4). Decreased contents of cystine
and sialic acid have been reported in diabetic kidney (5).
Changes in the renal handling of some amino acids in
diabetic kidney have also been suggested (6).
Biotinidase (EC 3.5.1.12), an amidase that hydrolyses
biocytin, is present in the microsome fraction (endoplas-
mic reticulum) of guinea pig and rat livers (7, 8), and
the activity of this enzyme in pig and rat has been shown
to be highest in the kidneys (8—10). This enzyme from
human serum also recognizes lipoyl-amide compounds
(11, 12) and enkephalin (13). From studies on biotini-
dase deficiency (14), it has been suggested that one of
the major biological roles of biotinidase is to recycle
biotin. Studies on patients with biotinidase deficiency
(15) also indicate that kidney biotinidase functions in
the re-uptake of biotin and biocytin. Elevated alanine
levels in urine of biotinidase deficient patients have also
been recently reported (16). Biotinidase has been shown
to be detectable in various renal diseases (17). Therefore,
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we compared biotinidase and alanine excretion in the
urine of diabetics and controls in order to clarify the role
of biotinidase in the kidney.
Materials and Methods
Patients
Patients (n = 21, female n = 12, male n = 9) with juvenile onset
diabetes mellitus: 17 outpatient and 4 hospitalized cases from the
National Children's Hospital (Tokyo, Japan).
Clinical profiles in 21 patients with insulin-dependent diabetes
mellitus: Age, 13.0 years (median), 3—26 years (range); Duration
of insulin-dependent diabetes mellitus, 5.0 years (median), 0—22
years (range); Blood pressure, systolic 14.5 ±2.13 (mean ± SD)
kPa, diastolic 8.53 ± 1.60 kPa; Treatment: Insulin requirement,
53.6 ± 35.4 U/d, 38 ± 19 U/m2 body surface area; Diet, 6750-
8400 kJ/d (1600-2000 kcal/d); Laboratory findings: Serum creati-
nine, 45.8 ± 3.8 μιηοΐ/ΐ; blood urea nitrogen 2.30 ± 0.566 mmol/1;
total cholesterol, 4.58 ± 0.698 mmol/1; HDL-cholesterol, 1.55
± 0.388 mmol/1; triacylglycerols, 850± 420 mg/1; fructosamine,
3.16 ± 0.82 μηιοΐ/ΐ; HbA,, 10.18 ± 2.1%, HbAlc (HPLC method
using polymer gel), 8.07 ± 1.9%; volume of urine, median 1.2801,
range 0.620-2.2001; urine glucose, 15.49 ±19.88 g/d; creatinine
clearance, 2.145 ± 1.332 ml/s X m2 body surface area. All of the
diabetic group received a diabetic diet and insulin, produced in
USA (Lilly) and Denmark (Novo Nordisk). Insulin was injected
2—4 times per day but one of the hospitalized patients received
pump insulin injection. In addition, one diabetic patient was treated
with steroid and another with thyroxin for to concomitant diseases.
Preproliferative diabetic retinopathy was marked in 3 patients, 1
had transitional proteinuria with 22 years of duration, 1 had bu-
limia. Concomitant diseases: nephrosis, one patient; thyroid distur-
bance, one patient; hand abnormality, one patient; Down's syn-
drome, one patient.
Healthy controls
Healthy volunteers (n = 10; female 4, male 6) of the institute. All
the volunteers were free from anomalies or pathology of kidneys,
urinary tract infection, and other acute infections. Characteristics
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of healthy controls: Age, 12.0 years (median), 7—50 years (range);
volume of urine, 0.885 1 (median), 0.624-2.9611 (range).
USA). Filtered urine samples were diluted 40-fold with 0.1 mol/1
HC1, and a 0.01 ml portion was injected into the HPLC system.
Specimens
Twenty-four-hour urine samples were collected from diabetic pa-
tients. After measuring the total volume, an aliquot was filtered
(Ekicrodisc 13; 200 nm pore size Versapor, Gelman Sciences Ja-
pan, Ltd., Tokyo, Japan) and stored at -80 °C.
Chemicals and reagents
Biotinyl-6-aminoquinoline and biocytin were purchased from
Sigma Chemical Co., St. Louis, MO, USA. 6-Aminoquinoline was
from Aldrich Chemical Co., Milwaukee, WI, USA. L-Amino acid
standards were from Takara Kohsan Co., Ltd., Tokyo, Japan. Poly-
oxyethylene (20) cetyl ether (Brij-58), glycerol, o-phthalaldehyde
and l,2-diamino-4,5-methylenedioxybenzene dihydrochloride were
from Wako Pure Chemical Co., Osaka, Japan. Sialic acid (N-ace-
tylneuraminic acid) was from Nacalai Tesque, Inc., Kyoto, Japan.
Develosil ODS-10 (octadecylsilane-bonded silica gel for high-per-
formance liquid chromatography) was from Nomura Chemical Co.,
Seto, Aichi, Japan.
Miscellaneous urine analyses
Free and total sialic acid was measured by an HPLC-fluorimetric
method (21). N-Acetyl- -glucosaminidase activity was measured
in 12 samples out of 21 patient urines by a photometric method
using 6-methyl-2-pyridyl-N-acetyl- -glucosamine as substrate
(Nittobo Medical Co., Tokyo, Japan). C-peptide was measured in
20 samples out of 21 patient urines by a RIA method (using sam-
ples stored at -80°C).
Statistical analysis
Non-parametric statistical analysis was performed. Mann-Whitney's
U test was used for assessing the significance of the difference of
two groups. Spearman's rank correlation coefficients (rS) were
used for estimating correlations between two groups. Calculations
were performed on a personal computer (Epson PC-485GR Super,
Seiko-Epson Co., Suwa-City, Nagano 392, Japan), using the soft-
ware: Statflex Lite, Version 2 (J. I. P. Co., Tokyo, Japan). A prob-
ability value below 0.01 was considered to be significant.
Biotinidase
Biotinidase activity in urine was measured by the high-perform-
ance liquid chromatography (HPLC) fluorometric method (17)
using biotinyl-6-aminoquinoline as substrate. Biotinyl-6-amino-
quinoline was dissolved at 0.044 mmol/1 (16.3 mg/1) in 0.1 mol/1
sodium phosphate buffer (pH 7.0) containing 1 mmol/1 (452 mg/1)
Na-EDTA and 10 mmol/1 (781 mg/1) 2-mercaptoethanol. Substrate
in 0.090 ml of the reaction buffer was mixed with 0.010 ml of
enzyme solution. Thus, the reaction mixture (0.100 ml) contained
1.468 μg (3.96 nmol) of biotinyl-6-amino-qumoline, 0.040 mg of
EDTA and 0.070 mg of 2-mercaptoethanol. The reaction was al-
lowed to proceed for an appropriate time at 37 °C, then stopped
by adding 0.200 ml of methanol; the reaction mixture was diluted
three-fold with methanol to precipitate the enzyme proteins. After
centrifugation and deproteinization at 1500 g for 15 min, a portion
(0.010 ml) of the clear supernatant was injected into the HPLC
system. The HPLC system for biotinidase assay consisted of a
model 600E HPLC pump (Waters Associates, Inc., Milford, MA,
USA), an injector (model U6K), a reversed-phase column (octade-
cylsilane bonded silica gel; 10 μπι sphere; 50 X 4.0 mm I. D.), and
a detector (model F-3000 fluorescence spectrophotometer, Hitachi,
Tokyo, Japan). The product 6-aminoquinoline was separated by the
reversed-phase column, and measured at an excitation wavelength
of 350 nm and an emission wavelength of 550 cm. The rate of
release of 6-aminoquinoline from substrate was calculated as pre-
viously described (17).
Biotinidase activity was also determined by measuring the release
of Ζ,-lysine from biocytin (0.152 mmol/1), using an HPLC amino
acid analyser according to the method described previously (13).
An enzyme unit was defined according to Ochoa et al. (18), i.e.
one unit was the amount of enzyme catalysing the release of
1 nmol of 6-aminoquinoline per minute at 37 °C from biotinyl-6-
aminoquinoline or 1 nmol of lysine from biocytin. Specific activity
was expressed as units per mg of (urinary) protein. The values
were multiplied by 1000 in order to obtain International Units (l U
= 1 μιηοΐ/min).
Urinary proteins and albumin determinations
Proteins and albumin in the urine were determined by sensitive
high-performance gel-permeation chromatography as described
previously (19).
Free amino acid measurements
Free L-amino acids were measured by using an HPLC amino-acid
analyser (Na+-type) as described previously (20) connected with
an autosampler (model AS-100, Βίο-Rad, Richmond, CA 94804,
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Fig. 1 Urinary 24-hour excretions of biotinidase in patients with
insulin-dependent diabetes mellitus (n = 21) and in controls
(n = 10). Biotinidase activity was determined using biotininyl-6-
aminoquinoline as substrate, and calculated as described in the Ma-
terials and Methods section.
Tab. 1 Differences in biotinidase and free amino acid excretions
per day between insulin-dependent diabetes mellitus patients and
normal controls.*
Difference
n-fold
Diabetics
(n = 21)
Median
Range
Controls
(n = 10)
Median
Range
Biotinidase3 —
Alanine" 2.21 -fold
Valineb 1.79-fold
Phenylalaninec 1.52-fold
Histidinec 2.10-fold
7.02
0.00-34.2
812
215-1714
69.0
0-214
160
0-360
2419
238-4830
0.00
0.00-10.9
368
147-895
38.5
17.5-100
105
41-76
1152
538-2604
* Biotinidase excretion was expressed as mU/d. Amino acid excre-
tion was expressed as μτηοΐ/d. Significance was calculated from
Mann-Whitney's U test. (a p < 0.005; b p < 0.01; c p < 0.05).
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Results and Discussion
It was found that 67% (14/21) of patients showed posi-
tive or pathological biotinidase excretion as compared
to a control level of 10% (1/10); i.e., the cut-off level
for negativity was defined as 90% of controls (fig. 1).
As shown in table 1, this elevation was found to be sig-
nificant (p < 0.005) as estimated by Mann-Whitney's U
test. There were no statistically significant differences
between the controls and patients with respect to age
and sex, according to Mann-Whitney's U test for age and
Fisher's exact test for sexes, respectively.
As also shown in figure 2 and table 1, only alanine and
valine excretion were significantly (p < 0.01) increased
in diabetic urine. Other amino acids and analytes, such
as free sialic acid, total proteins, and albumin were not
significantly elevated.
Urinary biotinidase and albumin have similar molecular
masses and different characteristics, which are summa-
rized in table 2. Although biotinidase and albumin have
similar acidic pi values, their excretion showed no cor-
relation at all (tab. 3). Biotinidase excretion showed a
positive correlation (rS = 0.667; p < 0.01) with alanine
excretion (tab. 3). Thus, the urines of insulin-dependent
diabetes mellitus patients show simultaneous elevations
of biotinidase and alanine excretion, which are posi-
tively correlated. In the control group, biotinidase excre-
tion (n = 3) was not correlated with alanine excretion.
Normal energy metabolism, as determined by the pro-
duction and utilization of ATP and NADH, is known to
be essential for kidney preservation and transplantation
(22, 23). It is also known that kidney is the tissue con-
taining the highest biotinidase activity in pig (9).
Baumgartner et al. (15) have suggested that kidney bio-
tinidase functions in the reabsorption of biotin and bio-
cytin. The active transport of L-alanine in bacteria has
been demonstrated using NADH or ascorbate plus phen-
azine methosulphate as energy sources (24). Therefore,
kidney biotinidase and the alanine transport system may
be linked through the energy metabolism of the kidney.
Biotinidase excretion into urine is certainly pathophysi-
ological (tab. 1 in I.e. (19)), although the simultaneous
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Fig. 2 Urinary 24-hour excretions of alanine in patients with in-
sulin-dependent diabetes mellitus (n = 21) and in controls
(n = 10). Alanine was determined with an HPLC amino acid ana-
lyser as described in the Materials and Methods section.
Tab. 2 Summary of some differences between biotinidase and al-
bumin in urine3.
Characteristics
Relative molecular mass
Isoelectric point (pi)
Glyco-chain
Subcellular distribution
in tissue
Enzyme activity
Hydrophilicity (%)b
Protein
Biotinidase
66000
4.4
O-glycoside
Microsome
(Endoplasmic
reticulum)
with
42.7
Albumin
66000
4.9
-
-
without
52.1
3
 Manuscript in preparation.
b
 Hydrophilicity is defined as the percentage of hydrophilic amino
acids; (Asx + Thr + Ser + Glx + Lys + His + Arg)/(total amino
acid) X 100(%) (7).
Tab. 3 Summary of significant correlations among excretions of several proteins in the urine of
insulin-dependent diabetes mellitus patients3.
rSs to
Alanine
Duration
Biotinidase
Albumin
Total proteins
Elevation of excretion0
Protein
Biotinidase
0.667 (p < 0.01)
No
-
-
-
Yes
Albumin
No
No
No
-
-
No
Total proteins
No
No
No
0.794 (p < 0.01)
-
No
N-Acetyl-
-glucosaminidaseb
No
No
No
No
No
ND
3
 Spearman''?, rank correlation coefficient (rS) was used. A prob-
ability value below 0.01 was considered to be significant. No;
p>0.01.
b
 ND; not determined.
c
 Compared with the control level. Mann-Whitney's U test was
used. A probability value below 0.01 was also considered to be
significant or Yes.
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elevation of biotinidase and alanine is rare. To determine
whether the simultaneous elevation of biotinidase and
alanine excretion is possibly the earliest detectable
manifestation of a predisposition to diabetic nephropa-
thy, we re-inspected our urinary data of 21 insulin-de-
pendent diabetes mellitus patients. It was found that 8
out of 21 patients (38%) showed elevated excretion of
both biotinidase and alanine. This value of 38% is sim-
ilar to the cumulative risk of nephropathy (30—40%).
Since preliminary studies suggest that early morning
urine is as suitable as 24-hour urine for these studies,
monitoring of these eight patients is expected to con-
tinue.
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